Financial Performance - Revenue for Q3 2023 reached ¥115,878,873.28, an increase of 9.23% compared to the same period last year, but a decrease of 37.66% year-to-date[4] - Net profit attributable to shareholders for Q3 2023 was ¥8,355,862.63, down 73.87% year-on-year, and down 72.43% year-to-date[4] - Basic earnings per share for Q3 2023 was ¥0.04, a decrease of 75.00% compared to the same period last year[4] - The total operating revenue for the third quarter of 2023 was CNY 351,192,635.35, a decrease of 37.5% compared to CNY 563,363,651.68 in the same period last year[25] - The net profit for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% compared to CNY 151,155,941.78 in Q3 2022[26] - Operating profit for Q3 2023 was CNY 44,871,999.14, down 73.6% from CNY 169,888,387.28 in Q3 2022[26] - The total comprehensive income for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% from CNY 151,155,941.78 in the same quarter last year[27] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.21, compared to CNY 0.76 in Q3 2022[27] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,755,601,460.68, a decrease of 2.35% from the end of the previous year[4] - The total assets as of September 30, 2023, were CNY 4,755,601,460.68, down from CNY 4,869,919,341.29 at the beginning of the year, a decrease of 2.3%[23] - The total liabilities decreased to CNY 234,780,503.70 from CNY 249,143,294.88, indicating a reduction of 5.8%[23] - The company's equity attributable to shareholders decreased to CNY 4,520,820,956.98 from CNY 4,620,776,046.41, a decline of 2.2%[23] Cash Flow - Cash flow from operating activities for the first nine months of 2023 was ¥21,942,222.52, down 75.73% year-on-year due to increased market competition[11] - Cash flow from operating activities generated a net amount of CNY 21,942,222.52, significantly lower than CNY 90,426,851.62 in the previous year[30] - The company's cash and cash equivalents decreased to CNY 117,966,133.78 from CNY 489,042,093.26 at the beginning of the year, representing a decline of 75.9%[21] - The company experienced a cash and cash equivalents net decrease of CNY -363,462,995.99, compared to an increase of CNY 256,890,519.32 in Q3 2022[30] - Total cash flow from investment activities was negative at CNY -251,828,518.11, compared to CNY -3,282,248,061.08 in the same period last year[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,770[13] - The total number of restricted shares at the beginning of the period was 92,946,000, with no shares released during the period, maintaining the same amount at the end[16] - 24,780,000 shares were released from restrictions for Shandong Luxin Qisheng Investment Management Co., Ltd. on February 10, 2023[16] - The company has a total of 12,852,000 restricted shares held by the shareholder Moxian, which were also released on February 10, 2023[16] - The management's locked shares include 2,160,000 shares for Li Dechun, with 25% of the total shares eligible for circulation each year during the tenure[16] - The shareholder Wang Meihua holds 2,745,395 shares, with 91,000 shares held through a regular account and 2,653,995 shares through a margin account[16] - The company reported a total of 5,400,000 restricted shares held by Shandong Kexin Venture Capital Co., Ltd., which were released on February 10, 2023[16] - The shareholder Zhang Yanjie has 2,206,697 restricted shares, all of which were released on February 10, 2023[16] - The total number of restricted shares held by the management team is subject to a 25% annual release during their tenure[16] - The company has a total of 1,137,258 restricted shares held by the shareholder Wang Meihua, which are also subject to the same release conditions[16] - The company has not disclosed any relationships or agreements among the top ten unrestricted shareholders[16] Operational Changes - The company decided to cancel the plan to use CNY 790 million of raised funds for permanent working capital supplementation due to lower than expected working capital needs[19] - The company held meetings to approve changes to its business scope and amendments to its articles of association to align with current operational needs[18] Other Income - Investment income for the first nine months of 2023 was ¥83,866,978.78, an increase of 39.56% compared to the same period last year[10] - Other income for the first nine months of 2023 was ¥821,692.01, a decrease of 87.55% year-on-year due to reduced government subsidies[10] Research and Development - Research and development expenses increased to CNY 36,626,985.64, up 14.5% from CNY 31,870,190.36 in the same period last year[26]

Financial Performance - The company's revenue for the first half of 2023 was ¥235.31 million, a decrease of 48.54% compared to ¥457.28 million in the same period last year[26]. - The net profit attributable to shareholders was ¥33.32 million, down 72.04% from ¥119.18 million year-on-year[26]. - The net cash flow from operating activities was ¥245.78 thousand, a significant decline of 99.24% compared to ¥32.36 million in the previous year[26]. - Basic and diluted earnings per share were both ¥0.16, representing a decrease of 73.77% from ¥0.61 in the same period last year[26]. - The total assets at the end of the reporting period were ¥4.71 billion, a decrease of 3.24% from ¥4.87 billion at the end of the previous year[26]. - The net assets attributable to shareholders decreased by 2.34% to ¥4.51 billion from ¥4.62 billion at the end of the previous year[26]. - The company's gross profit margin for the first half of 2023 was only 0.12%, a sharp decline from 41.99% in 2021 and 14.06% in 2022, reflecting increased cost pressures[120]. - The company's production capacity utilization rate was below 50% in the first half of 2023, indicating a risk of overcapacity in the erythritol market[123]. Market and Industry Trends - The company operates in the functional sugar industry, focusing on the research, production, and sales of products like erythritol and allulose[34]. - The functional sugar market has seen a surge in demand due to the rising trend of sugar reduction, with erythritol becoming a widely used sweetener across various sectors[35]. - Recent government policies support the functional sugar industry, promoting health-conscious consumption and encouraging the use of low-sugar alternatives[39]. - The "Healthy China 2030" initiative emphasizes the importance of health and nutrition, which aligns with the company's product offerings[40]. - The competitive landscape has intensified, with many new entrants in the erythritol market, impacting overall profitability[37]. - The anticipated growth in the sugar-free beverage market will further drive the downstream demand for erythritol[44]. Research and Development - The company is committed to innovation in product development to meet the evolving consumer preferences for healthier options[35]. - The company focuses on the research and development of functional sugars, particularly erythritol and allulose, to meet the growing demand for health-oriented products[47]. - The company has developed a new strain of yeast that can increase the purity of residual erythritol from below 50% to over 70%, and further to 80% after repeated trials, enhancing extraction efficiency[70]. - Research and development investment amounted to ¥21,561,358.95, a slight decrease of 2.85% from ¥22,192,798.83 in the previous year[79]. Corporate Governance and Shareholder Relations - The company emphasizes the protection of shareholder rights and has established a robust governance structure to enhance operational transparency[136]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[5]. - The controlling shareholder and senior management have committed to not transferring or entrusting the management of their shares for 36 months post-IPO[141]. - The company has established a clear framework for share management to align with corporate governance standards[141]. - The company has committed to improving its profit distribution policy to enhance investor returns, particularly focusing on independent directors and minority shareholders' feedback[147]. Cash Management and Fund Utilization - The company plans to use up to RMB 2.4 billion of temporarily idle raised funds for cash management, effective for 12 months from the approval date[170]. - The company has incurred a net income of RMB 1,232.49 million from interest on the raised funds[98]. - The total amount raised from the initial public offering was CNY 368,570.53 million, with a net amount of CNY 354,664.46 million after deducting issuance costs of CNY 13,906.07 million[102]. - The company will strengthen fundraising management to ensure that the raised funds are used for their intended purposes and achieve expected benefits[147]. Strategic Outlook - The company provided a positive outlook for the second half of 2023, expecting continued growth and market expansion[142]. - The company aims to expand its market presence in key regions, targeting a 15% increase in market share by the end of 2024[142]. - The company is exploring strategic acquisitions to enhance its market position and product offerings[142]. - The company plans to enhance its product range by accelerating the development of new products such as allulose and high-quality stevia sugar, aiming to diversify its offerings[115]. Compliance and Regulatory Matters - The company has updated its pollutant discharge permit, valid from August 24, 2022, to August 23, 2027, indicating compliance with environmental regulations[133]. - The company adheres to ISO 14001 environmental management standards, ensuring sustainable production practices[134]. - The semi-annual financial report for 2023 has not been audited yet, which is standard practice for this period[154]. - The company has maintained a clean integrity status with no penalties or rectifications required[156].

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company's total revenue for the current period was CNY 563,363,651.68, a decrease of approximately 56.7% compared to CNY 1,305,360,240.59 in the same period last year[27] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in Q3 2021[28] - Operating profit for the quarter was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, the total assets of Shandong Sanyuan Biotechnology Co., Ltd. amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[23] - The total liabilities of the company as of September 30, 2022, were CNY 189,942,474.74, down from CNY 588,828,870.18, a reduction of approximately 67.8%[25] Equity and Shareholder Information - The company reported a significant increase in total equity attributable to shareholders, which reached CNY 4,608,245,346.85, up 340.84% from the previous year[4] - The equity attributable to the owners of the parent company increased to CNY 4,608,245,346.85 from CNY 1,045,328,564.67, reflecting a growth of about 340.5%[25] - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, totaling 92,946,000 shares[14] - The company completed a capital increase from capital reserves, increasing the total share capital from 134,883,800 shares to 202,325,700 shares, with a distribution of 5 shares for every 10 shares held[19] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, down 82.62% compared to the previous year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 in the previous year[28] Operational Changes - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its credibility and operational efficiency in international trade[21] - The company has changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, indicating a strategic shift in its auditing approach[20] - The company has not disclosed any related party relationships among the top ten shareholders[15] - The company has not reported any new product developments or market expansion strategies during the reporting period[18] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, indicating a reduction of approximately 76.3%[23] - Inventory levels decreased to CNY 73,203,380.23 from CNY 112,157,402.58, representing a decline of about 34.7%[24] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2022, were CNY 514,413,874.36, slightly down from CNY 515,719,690.44 at the beginning of the year[23] - The company reported a total cash and cash equivalents balance of CNY 514,832,741.03 at the end of the quarter, compared to CNY 254,249,794.17 at the end of Q3 2021[31]

Financial Performance - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - Basic and diluted earnings per share fell by 26.09% to ¥0.51 from ¥0.69 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase from CNY 263,493,075.06 in the previous period[20] - Net profit for Q1 2022 was CNY 62,765,994.16, down from CNY 69,465,064.33 in the previous period, indicating a decrease of approximately 9.7%[21] - Earnings per share for Q1 2022 were CNY 0.51, compared to CNY 0.69 in the previous period, showing a decline[22] Cash Flow - The net cash flow from operating activities dropped significantly by 84.24% to ¥20,443,976.73, down from ¥129,686,530.82 in the previous year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[25] - Total cash inflow from financing activities was ¥3,573,401,313.01, while cash outflow was ¥22,336,495.47, resulting in a net cash flow of ¥3,551,064,817.54[26] - The net increase in cash and cash equivalents for the period was ¥9,191,788.52, compared to an increase of ¥83,423,153.69 in the previous year[26] - The total cash and cash equivalents at the end of the period stood at ¥267,134,010.23, up from ¥141,186,753.95 at the end of Q1 2021[26] - The company reported cash inflow from operating activities totaling ¥312,922,891.80, an increase from ¥290,470,739.70 in the same period last year[25] - Cash outflow for purchasing goods and services was ¥266,221,244.95, significantly higher than ¥139,392,617.05 in Q1 2021[25] - The company recorded cash inflow from investment activities of ¥477,900.00, while cash outflow was ¥3,563,181,945.45, leading to a net cash flow of -¥3,562,704,045.45[25] - The company received ¥3,567,762,730.40 from investment activities, indicating strong capital inflow during the quarter[26] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 compared to ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in the previous period[18] - The company's equity attributable to shareholders was CNY 4,654,908,120.59, significantly higher than CNY 1,045,328,564.67 in the previous period[18] - Deferred income tax liabilities increased to CNY 25,228,040.35 from CNY 23,025,951.67 in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21.906 million[11] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[11] Investment and Subsidiary Activities - The company raised a total of RMB 3,685,705,300 from the public offering of 33.721 million shares at RMB 109.3 per share[13] - The net amount raised after deducting issuance costs was RMB 3,546,644,640.40[13] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million[14] Other Financial Metrics - Cash received from tax refunds increased by 47.42%, primarily due to an increase in VAT refunds during the reporting period[8] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to rising raw material prices and a shift in payment methods[8] - Other payables increased by 44.69%, mainly due to an increase in customer deposits for yeast mud sales[9] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, slightly down from CNY 11,579,638.16 in the previous period[21] Audit Status - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[27]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company's operating revenue for the reporting period was approximately ¥457.28 million, a decrease of 41.89% compared to the same period last year[26]. - The net profit attributable to shareholders was approximately ¥119.18 million, down 50.93% year-on-year[26]. - The net cash flow from operating activities was approximately ¥32.36 million, reflecting a significant decline of 88.16% compared to the previous year[26]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 20%[111]. - The company reported a net profit for the first half of 2022 of CNY 119,527,796.34, a decrease of 50.7% compared to CNY 242,889,853.19 in the same period of 2021[184]. - The total revenue for the first half of 2022 was CNY 5,557,800,000, representing a year-on-year increase of 33.7%[194]. Profitability and Margins - The gross profit margin improved to 35%, up from 30% in the same period last year[17]. - The company achieved a gross margin of 18.33% for erythritol, down 22.37% year-on-year, with revenue decreasing by 47.36%[56]. - The overall gross profit margin decreased from 42.27% in 2020 to 21.30% in the first half of 2022, reflecting challenges in maintaining high profitability[89]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[110]. - The company reported a significant increase in retained earnings, contributing to a stronger equity position[193]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[17]. - Investment in R&D increased by 25% year-on-year, focusing on innovative biotechnology solutions[110]. - The company is focusing on R&D in synthetic biology and has established a wholly-owned subsidiary to enhance its technological capabilities[49]. - The company has set a target to increase its R&D investment to 10% of total revenue, emphasizing the importance of innovation in its growth strategy[117]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2025[17]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[110]. - The company plans to focus on market demand by vigorously developing new technologies and products, aiming to launch high-value-added products that meet market needs[90]. - A strategic acquisition of a local biotech firm is anticipated to enhance product offerings and accelerate growth[110]. Operational Efficiency - The conversion rate of raw materials to end products improved to 85% in the reporting period[15]. - The company has adopted a procurement model based on "production-driven ordering and price comparison," ensuring efficient supply chain management[34]. - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[110]. - The company aims to improve its operational efficiency, targeting a reduction in production costs by 5% through process optimization[111]. Shareholder and Capital Management - No cash dividends or stock bonuses will be distributed for this fiscal year[5]. - The company has not reported any changes in fundraising projects during the reporting period[76]. - The company has a commitment to not transfer or delegate the management of shares held prior to the public offering for 12 months[109]. - The company will prioritize measures such as stock repurchase, shareholding increase by controlling shareholders, and management stock purchases to stabilize the stock price[112]. Risk Management - The company faces risks related to supply chain disruptions and has implemented measures to mitigate these risks[4]. - The company faced a risk of intensified market competition in the erythritol industry, which could lead to price declines and increased sales expenses[83]. - The company acknowledges the existence of internal and external risks that may affect future profits, despite measures to protect shareholder interests[115]. Compliance and Governance - The company adheres to the ISO14001 environmental management system standards, ensuring compliance with environmental protection laws and regulations[102]. - The management emphasized the importance of adhering to regulatory compliance and maintaining shareholder trust during the upcoming growth phase[111]. - The company will publicly disclose reasons for not implementing stabilization measures if conditions are met but not acted upon, and will apologize to investors[112]. Assets and Liabilities - The total assets at the end of the reporting period reached approximately ¥4.87 billion, an increase of 198.26% from the end of the previous year[26]. - The company's total liabilities decreased to CNY 297,710,441.18 from CNY 588,828,870.18, indicating a reduction of approximately 49.6%[174]. - The equity attributable to the parent company increased significantly to CNY 4,576,268,962.21 from CNY 1,045,328,564.67, marking an increase of around 338.5%[174].

证券代码：301206 证券简称：三元生物 公告编号：2024-006 山东三元生物科技股份有限公司 2024 年第一次临时股东大会通知公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第十九 次会议决定于 2024 年 2 月 20 日（星期二）召开公司 2024 年第一次临时股东大 会，现将本次会议有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2024 年第一次临时股东大会 （二）股东大会的召集人：公司董事会。 （三）会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开的日期、时间： 1、现场会议召开时间：2024 年 2 月 20 日（星期二）15:00 2、网络投票时间：2024 年 2 月 20 日（星期二） （2）通过深圳证券交易所互联网系统投票的时间为 2024 年 2 月 20 日 9:15-15:00 （五）会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方 式召开。 1 / 9 ...

中信建投证券股份有限公司 关于山东三元生物科技股份有限公司 使用部分暂时闲置自有资金进行现金管理 的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"）首次 公开发行股票并在创业板上市之保荐机构，根据《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关规定，中信建投证券对三元生物拟使用部分暂时闲置自有资金进 行现金管理的事项进行了核查，核查的具体情况如下： 一、前次使用部分暂时闲置自有资金进行现金管理的基本情况 公司于 2023 年 2 月 8 日召开了第四届董事会第十四次会议和第四届监事会 第十一次会议，于 2023 年 2 月 24 日召开了 2023 年第一次临时股东大会，上述 会议审议通过了《关于使用部分暂时闲置自有资金进行现金管理的议案》。同意 公司在不影响正常生产、经营及确保资金安全的前提下，拟使用不超过 220,000 万元人民币暂时闲置自有资金进行现金管理。使用期限自公司 2023 年第一次临 时股东大会审议通过之日起 12 个月内有效 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-003 本次会议以记名投票表决方式表决通过如下议案： （一）审议通过《关于继续使用部分暂时闲置募集资金（含超募资金）进 行现金管理的议案》； 山东三元生物科技股份有限公司 第四届监事会第十五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2024 年 2 月 2 日下午 2:30 在公司会议室以现场方式召开。会议通知于 1 月 29 日以书面、电话方式通知到各位监事，本次会议应到监事 3 人，实到监 事 3 人，会议由监事会主席崔振乾主持，会议的召集、召开和表决程序符合《公 司法》和《公司章程》的有关规定，所作决议合法有效。 二、议案审议情况 为提高募集资金使用效率，合理利用闲置资金，增加资金收益，结合募集资 金使用情况，在不影响募集资金投资项目建设和保证募集资金安全使用的前提下， 公司拟继续使用不超过 240,000 万元人民币暂时闲置募集资金（含超募资金）进 行现金管理（拟购买安 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-005 山东三元生物科技股份有限公司 关于继续使用部分暂时闲置自有资金进行现金管理的公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日 召开了第四届董事会第十九次会议、第四届监事会第十五次会议，会议审议通过 了《关于继续使用部分暂时闲置自有资金进行现金管理的议案》。为提高闲置自 有资金的使用效率，增加公司资金收益，同意公司在不影响正常生产、经营的前 提下，拟继续使用不超过 100,000 万元人民币暂时闲置自有资金进行现金管理。 使用期限自公司 2024 年第一次临时股东大会审议通过之日起 12 个月内有效，如 单笔交易的存续期超过了上述决议有效期，则有效期自动延续至单笔交易到期时 止，在上述投资额度和使用期限内资金可滚动使用。公司授权管理层在上述额度 范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公司财务部负责 组织实施。现将具体情况公告如下： 一、前次使用部分暂时闲置自有资金进行现金管理的基本情况 公 ...

山东三元生物科技股份有限公司 第四届董事会第十九次会议决议公告 证券代码：301206 证券简称：三元生物 公告编号：2024-002 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 度和使用期限内资金可滚动使用。暂时闲置募集资金（含超募资金）在现金管理 到期后将及时归还至募集资金专户。公司授权管理层在上述额度范围及期限内行 使投资决策、签署相关文件等事宜，具体事项由公司财务部负责组织实施。 具体内容详见公司于2024年2月3日在巨潮资讯网（www.cninfo.com.cn）披 露的《关于继续使用部分暂时闲置募集资金（含超募资金）进行现金管理的公告》 （公告编号：2024-004）。 表决结果：9 票同意，0 票反对，0 票弃权。 回避表决情况：本议案不涉及回避表决情况。 本议案尚需提交股东大会审议。 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第十九 次会议于 2024 年 2 月 2 日上午 9:30 在公司会议室以现场+视频方式召开。会议 通知于 1 月 29 日以书面、电话方式通知到各位董事，本次会议应到董事 9 ...